Disc Medicine Inc. i presented an overview of its pipeline and development strategy at the 44th Annual J.P. Morgan Healthcare Conference. The company highlighted its investigational agents, including Bitopertin, DISC-0974, and DISC-3405, which target key pathways in red blood cell biology. Bitopertin was featured as a potential therapy for erythropoietic protoporphyria $(EPP)$, a rare genetic disorder characterized by severe pain and skin damage due to light exposure, as well as possible liver complications. The presentation outlined the company’s plans for advancing its portfolio across a range of hematologic diseases, from rare conditions to those with broader prevalence. Disc Medicine also discussed its commercialization strategy and growth outlook through 2026 and 2027. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief on January 14, 2026, and is solely responsible for the information contained therein.